New  ||| S:0 E:4 ||| JJ
advances  ||| S:4 E:13 ||| NNS
in  ||| S:13 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
pathogenesis  ||| S:20 E:33 ||| NN
of  ||| S:33 E:36 ||| IN
ANCA-associated  ||| S:36 E:52 ||| JJ
vasculitides  ||| S:52 E:65 ||| JJ
Anti-neutrophil  ||| S:65 E:81 ||| JJ
cytoplasmic  ||| S:81 E:93 ||| JJ
antibody  ||| S:93 E:102 ||| NN
( ||| S:102 E:103 ||| -LRB-
ANCA ||| S:103 E:107 ||| NNP
) ||| S:107 E:108 ||| -RRB-
-associated  ||| S:108 E:120 ||| JJ
vasculitides  ||| S:120 E:133 ||| NNS
( ||| S:133 E:134 ||| -LRB-
AAV ||| S:134 E:137 ||| NNP
)  ||| S:137 E:139 ||| -RRB-
are  ||| S:139 E:143 ||| VBP
a  ||| S:143 E:145 ||| DT
group  ||| S:145 E:151 ||| NN
of  ||| S:151 E:154 ||| IN
autoimmune  ||| S:154 E:165 ||| JJ
disorders  ||| S:165 E:175 ||| NNS
including  ||| S:175 E:185 ||| VBG
Wegener ||| S:185 E:192 ||| NNP
's  ||| S:192 E:195 ||| POS
granulomatosis  ||| S:195 E:210 ||| NN
( ||| S:210 E:211 ||| -LRB-
WG ||| S:211 E:213 ||| NNP
) ||| S:213 E:214 ||| -RRB-
,  ||| S:214 E:216 ||| ,
microscopic  ||| S:216 E:228 ||| JJ
polyangiitis  ||| S:228 E:241 ||| NNS
( ||| S:241 E:242 ||| -LRB-
MPA ||| S:242 E:245 ||| NNP
) ||| S:245 E:246 ||| -RRB-
,  ||| S:246 E:248 ||| ,
Churg-Strauss  ||| S:248 E:262 ||| JJ
syndrome  ||| S:262 E:271 ||| NN
( ||| S:271 E:272 ||| -LRB-
CSS ||| S:272 E:275 ||| NNP
)  ||| S:275 E:277 ||| -RRB-
and  ||| S:277 E:281 ||| CC
renal-limited  ||| S:281 E:295 ||| JJ
vasculitis  ||| S:295 E:306 ||| NNS
( ||| S:306 E:307 ||| -LRB-
RLV ||| S:307 E:310 ||| NNP
) ||| S:310 E:311 ||| -RRB-
.  ||| S:311 E:313 ||| .
This  ||| S:313 E:318 ||| DT
paper  ||| S:318 E:324 ||| NN
reviews  ||| S:324 E:332 ||| VBZ
updated  ||| S:332 E:340 ||| VBN
information  ||| S:340 E:352 ||| NN
on  ||| S:352 E:355 ||| IN
the  ||| S:355 E:359 ||| DT
pathogenesis  ||| S:359 E:372 ||| NN
of  ||| S:372 E:375 ||| IN
AAV ||| S:375 E:378 ||| NNP
.  ||| S:378 E:380 ||| .
Additional  ||| S:380 E:391 ||| JJ
clinical  ||| S:391 E:400 ||| JJ
evidence  ||| S:400 E:409 ||| NN
for  ||| S:409 E:413 ||| IN
a  ||| S:413 E:415 ||| DT
pathogenic  ||| S:415 E:426 ||| JJ
role  ||| S:426 E:431 ||| NN
of  ||| S:431 E:434 ||| IN
ANCA  ||| S:434 E:439 ||| NNP
comes  ||| S:439 E:445 ||| VBZ
from  ||| S:445 E:450 ||| IN
the  ||| S:450 E:454 ||| DT
observation  ||| S:454 E:466 ||| NN
that  ||| S:466 E:471 ||| IN
patients  ||| S:471 E:480 ||| NNS
with  ||| S:480 E:485 ||| IN
severe  ||| S:485 E:492 ||| JJ
acute  ||| S:492 E:498 ||| JJ
renal  ||| S:498 E:504 ||| JJ
failure  ||| S:504 E:512 ||| NN
treated  ||| S:512 E:520 ||| VBN
with  ||| S:520 E:525 ||| IN
plasma  ||| S:525 E:532 ||| JJ
exchange  ||| S:532 E:541 ||| NN
had  ||| S:541 E:545 ||| VBD
a  ||| S:545 E:547 ||| DT
lower  ||| S:547 E:553 ||| JJR
risk  ||| S:553 E:558 ||| NN
for  ||| S:558 E:562 ||| IN
progression  ||| S:562 E:574 ||| VBG
to  ||| S:574 E:577 ||| TO
end-stage  ||| S:577 E:587 ||| JJ
renal  ||| S:587 E:593 ||| JJ
disease  ||| S:593 E:601 ||| NN
than  ||| S:601 E:606 ||| IN
patients  ||| S:606 E:615 ||| NNS
who  ||| S:615 E:619 ||| WP
received  ||| S:619 E:628 ||| VBD
intravenous  ||| S:628 E:640 ||| JJ
methylprednisolone  ||| S:640 E:659 ||| JJ
therapy ||| S:659 E:666 ||| NN
,  ||| S:666 E:668 ||| ,
both  ||| S:668 E:673 ||| DT
in  ||| S:673 E:676 ||| IN
addition  ||| S:676 E:685 ||| NN
to  ||| S:685 E:688 ||| TO
standard  ||| S:688 E:697 ||| JJ
treatment ||| S:697 E:706 ||| NN
.  ||| S:706 E:708 ||| .
Recent  ||| S:708 E:715 ||| JJ
data  ||| S:715 E:720 ||| NNS
also  ||| S:720 E:725 ||| RB
suggest  ||| S:725 E:733 ||| VB
that  ||| S:733 E:738 ||| IN
antibodies  ||| S:738 E:749 ||| NNS
to  ||| S:749 E:752 ||| TO
complementary  ||| S:752 E:766 ||| VB
proteinase-3  ||| S:766 E:779 ||| NNP
( ||| S:779 E:780 ||| -LRB-
cPR3 ||| S:780 E:784 ||| NNP
) ||| S:784 E:785 ||| -RRB-
,  ||| S:785 E:787 ||| ,
probably  ||| S:787 E:796 ||| RB
cross-reacting  ||| S:796 E:811 ||| JJ
with  ||| S:811 E:816 ||| IN
plasminogen ||| S:816 E:827 ||| NN
,  ||| S:827 E:829 ||| ,
may  ||| S:829 E:833 ||| MD
induce  ||| S:833 E:840 ||| VB
PR3-ANCA ||| S:840 E:848 ||| CD
.  ||| S:848 E:850 ||| .
Furthermore ||| S:850 E:861 ||| RB
,  ||| S:861 E:863 ||| ,
a  ||| S:863 E:865 ||| DT
new  ||| S:865 E:869 ||| JJ
ANCA ||| S:869 E:873 ||| NNP
,  ||| S:873 E:875 ||| ,
directed  ||| S:875 E:884 ||| VBN
against  ||| S:884 E:892 ||| IN
human  ||| S:892 E:898 ||| JJ
lysosome  ||| S:898 E:907 ||| FW
membrane  ||| S:907 E:916 ||| FW
protein-2  ||| S:916 E:926 ||| FW
( ||| S:926 E:927 ||| -LRB-
LAMP-2 ||| S:927 E:933 ||| NNP
) ||| S:933 E:934 ||| -RRB-
,  ||| S:934 E:936 ||| ,
concurrent  ||| S:936 E:947 ||| JJ
with  ||| S:947 E:952 ||| IN
PR3-ANCA  ||| S:952 E:961 ||| NNP
or  ||| S:961 E:964 ||| CC
MPO-ANCA ||| S:964 E:972 ||| JJ
,  ||| S:972 E:974 ||| ,
was  ||| S:974 E:978 ||| VBD
described  ||| S:978 E:988 ||| VBN
as  ||| S:988 E:991 ||| IN
a  ||| S:991 E:993 ||| DT
sensitive  ||| S:993 E:1003 ||| JJ
and  ||| S:1003 E:1007 ||| CC
specific  ||| S:1007 E:1016 ||| JJ
marker  ||| S:1016 E:1023 ||| NN
for  ||| S:1023 E:1027 ||| IN
renal  ||| S:1027 E:1033 ||| JJ
AAV ||| S:1033 E:1036 ||| NNP
.  ||| S:1036 E:1038 ||| .
In  ||| S:1038 E:1041 ||| IN
vitro ||| S:1041 E:1046 ||| NN
,  ||| S:1046 E:1048 ||| ,
ANCA  ||| S:1048 E:1053 ||| NNP
can  ||| S:1053 E:1057 ||| MD
further  ||| S:1057 E:1065 ||| RB
activate  ||| S:1065 E:1074 ||| VBP
primed  ||| S:1074 E:1081 ||| VBN
neutrophils  ||| S:1081 E:1093 ||| VBN
to  ||| S:1093 E:1096 ||| TO
release  ||| S:1096 E:1104 ||| VB
reactive  ||| S:1104 E:1113 ||| JJ
oxygen  ||| S:1113 E:1120 ||| NN
species  ||| S:1120 E:1128 ||| NNS
and  ||| S:1128 E:1132 ||| CC
lytic  ||| S:1132 E:1138 ||| JJ
enzymes ||| S:1138 E:1145 ||| NN
,  ||| S:1145 E:1147 ||| ,
and ||| S:1147 E:1150 ||| CC
,  ||| S:1150 E:1152 ||| ,
in  ||| S:1152 E:1155 ||| IN
conjunction  ||| S:1155 E:1167 ||| NN
with  ||| S:1167 E:1172 ||| IN
neutrophils ||| S:1172 E:1183 ||| NN
,  ||| S:1183 E:1185 ||| ,
damage  ||| S:1185 E:1192 ||| NN
and  ||| S:1192 E:1196 ||| CC
lyse  ||| S:1196 E:1201 ||| JJ
endothelial  ||| S:1201 E:1213 ||| JJ
cells ||| S:1213 E:1218 ||| NNS
.  ||| S:1218 E:1220 ||| .
In  ||| S:1220 E:1223 ||| IN
vivo ||| S:1223 E:1227 ||| NN
,  ||| S:1227 E:1229 ||| ,
transfer  ||| S:1229 E:1238 ||| NN
of  ||| S:1238 E:1241 ||| IN
splenocytes  ||| S:1241 E:1253 ||| NN
from  ||| S:1253 E:1258 ||| IN
myeloperoxidase-deficient  ||| S:1258 E:1284 ||| JJ
mice  ||| S:1284 E:1289 ||| NNS
immunized  ||| S:1289 E:1299 ||| VBN
with  ||| S:1299 E:1304 ||| IN
mouse  ||| S:1304 E:1310 ||| NN
myeloperoxidase  ||| S:1310 E:1326 ||| NN
into  ||| S:1326 E:1331 ||| IN
wild-type  ||| S:1331 E:1341 ||| JJ
mice  ||| S:1341 E:1346 ||| NNS
resulted  ||| S:1346 E:1355 ||| VBD
in  ||| S:1355 E:1358 ||| IN
pauci-immune  ||| S:1358 E:1371 ||| JJ
systemic  ||| S:1371 E:1380 ||| JJ
vasculitis ||| S:1380 E:1390 ||| NN
.  ||| S:1390 E:1392 ||| .
A  ||| S:1392 E:1394 ||| DT
similar  ||| S:1394 E:1402 ||| JJ
experiment  ||| S:1402 E:1413 ||| NN
in  ||| S:1413 E:1416 ||| IN
PR3-deficient  ||| S:1416 E:1430 ||| CD
mice  ||| S:1430 E:1435 ||| NNS
did  ||| S:1435 E:1439 ||| VBD
not  ||| S:1439 E:1443 ||| RB
cause  ||| S:1443 E:1449 ||| VB
significant  ||| S:1449 E:1461 ||| JJ
vasculitic  ||| S:1461 E:1472 ||| JJ
lesions ||| S:1472 E:1479 ||| NNS
.  ||| S:1479 E:1481 ||| .
In  ||| S:1481 E:1484 ||| IN
the  ||| S:1484 E:1488 ||| DT
anti-MPO  ||| S:1488 E:1497 ||| JJ
induced  ||| S:1497 E:1505 ||| JJ
vasculitis  ||| S:1505 E:1516 ||| JJ
mouse  ||| S:1516 E:1522 ||| NN
model ||| S:1522 E:1527 ||| NN
,  ||| S:1527 E:1529 ||| ,
a  ||| S:1529 E:1531 ||| DT
critical  ||| S:1531 E:1540 ||| JJ
role  ||| S:1540 E:1545 ||| NN
of  ||| S:1545 E:1548 ||| IN
complement  ||| S:1548 E:1559 ||| JJ
activation  ||| S:1559 E:1570 ||| NN
was  ||| S:1570 E:1574 ||| VBD
suggested ||| S:1574 E:1583 ||| VBN
.  ||| S:1583 E:1585 ||| .
The  ||| S:1585 E:1589 ||| DT
anti-  ||| S:1589 E:1595 ||| JJ
LAMP-2  ||| S:1595 E:1602 ||| CD
antibody  ||| S:1602 E:1611 ||| NN
can  ||| S:1611 E:1615 ||| MD
also  ||| S:1615 E:1620 ||| RB
induce  ||| S:1620 E:1627 ||| VB
pauci-immune  ||| S:1627 E:1640 ||| JJ
necrotizing  ||| S:1640 E:1652 ||| JJ
crescentic  ||| S:1652 E:1663 ||| JJ
glomerulonephritis  ||| S:1663 E:1682 ||| NN
in  ||| S:1682 E:1685 ||| IN
rats ||| S:1685 E:1689 ||| NNS
.  ||| S:1689 E:1691 ||| .
Rats  ||| S:1691 E:1696 ||| NNS
developed  ||| S:1696 E:1706 ||| VBD
both  ||| S:1706 E:1711 ||| DT
cross-reactive  ||| S:1711 E:1726 ||| JJ
antibodies  ||| S:1726 E:1737 ||| NNS
to  ||| S:1737 E:1740 ||| TO
LAMP-2  ||| S:1740 E:1747 ||| CD
and  ||| S:1747 E:1751 ||| CC
crescentic  ||| S:1751 E:1762 ||| JJ
glomerulonephritis  ||| S:1762 E:1781 ||| NN
when  ||| S:1781 E:1786 ||| WRB
immunized  ||| S:1786 E:1796 ||| NNS
with  ||| S:1796 E:1801 ||| IN
FimH ||| S:1801 E:1805 ||| NNP
,  ||| S:1805 E:1807 ||| ,
an  ||| S:1807 E:1810 ||| DT
adhesin  ||| S:1810 E:1818 ||| NN
from  ||| S:1818 E:1823 ||| IN
Gram-negative  ||| S:1823 E:1837 ||| JJ
bacteria  ||| S:1837 E:1846 ||| NNS
which  ||| S:1846 E:1852 ||| WDT
has  ||| S:1852 E:1856 ||| VBZ
strong  ||| S:1856 E:1863 ||| JJ
homology  ||| S:1863 E:1872 ||| NN
with  ||| S:1872 E:1877 ||| IN
human  ||| S:1877 E:1883 ||| JJ
LAMP-2 ||| S:1883 E:1889 ||| NN
.  ||| S:1889 E:1891 ||| .
Together ||| S:1891 E:1899 ||| RB
,  ||| S:1899 E:1901 ||| ,
clinical ||| S:1901 E:1909 ||| JJ
,  ||| S:1909 E:1911 ||| ,
in  ||| S:1911 E:1914 ||| IN
vitro  ||| S:1914 E:1920 ||| NN
and  ||| S:1920 E:1924 ||| CC
in  ||| S:1924 E:1927 ||| IN
vivo  ||| S:1927 E:1932 ||| JJ
data  ||| S:1932 E:1937 ||| NNS
support  ||| S:1937 E:1945 ||| VBP
a  ||| S:1945 E:1947 ||| DT
pathogenic  ||| S:1947 E:1958 ||| JJ
role  ||| S:1958 E:1963 ||| NN
for  ||| S:1963 E:1967 ||| IN
ANCA  ||| S:1967 E:1972 ||| NNP
in  ||| S:1972 E:1975 ||| IN
AAV ||| S:1975 E:1978 ||| NNP
,  ||| S:1978 E:1980 ||| ,
although  ||| S:1980 E:1989 ||| IN
this  ||| S:1989 E:1994 ||| DT
role  ||| S:1994 E:1999 ||| NN
is  ||| S:1999 E:2002 ||| VBZ
more  ||| S:2002 E:2007 ||| RBR
evident  ||| S:2007 E:2015 ||| JJ
for  ||| S:2015 E:2019 ||| IN
myeloperoxidase-ANCA  ||| S:2019 E:2040 ||| JJ
than  ||| S:2040 E:2045 ||| IN
for  ||| S:2045 E:2049 ||| IN
PR3-ANCA ||| S:2049 E:2057 ||| CD
.  ||| S:2057 E:2059 ||| .
The  ||| S:2059 E:2063 ||| DT
role  ||| S:2063 E:2068 ||| NN
of  ||| S:2068 E:2071 ||| IN
anti-  ||| S:2071 E:2077 ||| NNP
LAMP-2  ||| S:2077 E:2084 ||| NNP
requires  ||| S:2084 E:2093 ||| VBZ
further  ||| S:2093 E:2101 ||| JJ
studies ||| S:2101 E:2108 ||| NNS
.  ||| S:2108 E:2110 ||| .
